Intravenous Hydroxypropyl β‐Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single‐Ascending, and Multiple‐Dose Trial-Reference-Cited by-同舟云学术

Intravenous Hydroxypropyl β‐Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single‐Ascending, and Multiple‐Dose Trial

Published:2017-07-04 Issue:6 Volume:10 Page:487-495
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Erb‐Zohar K¹,Kropeit D²,Scheuenpflug J³,Stobernack H‐P²,Hulskotte EGJ⁴,Schanke A⁵,Zimmermann H²,Rübsamen‐Schaeff H²

Affiliation:

1. clinphase Hanau Germany

2. AiCuris Anti‐infective Cures GmbH Wuppertal Germany

3. Merck Biopharma Darmstadt Germany

4. Merck Sharp & Dohme The Netherlands

5. Quantitative Solutions BV, Oss The Netherlands

Funder

Merck

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12483

Reference16 articles.

1. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

2. Antiviral Treatment of Cytomegalovirus Infection

3. Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

4. Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

5. Letermovir (AIC246) a novel drug under development for prevention and treatment of cytomegalovirus infections acting via a novel mechanism of action;Zimmermann H.;Eur. Infect. Dis,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation;Clinical Pharmacokinetics;2024-07

2. Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir;Infectious Disease Reports;2024-01-18

3. Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling;Clinical and Translational Science;2023-04-21

4. Cyclodextrin-based delivery systems in parenteral formulations: A critical update review;European Journal of Pharmaceutics and Biopharmaceutics;2022-09

5. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients;Antimicrobial Agents and Chemotherapy;2022-08-16